Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 16/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Noraristeromycin SCHEMBL19644993 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL8886019 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL26381984 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL17117186 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL17109603 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL29378522 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| SCHEMBL12149495 | 0.93 | AHCY (0.86) | AHCYADORA2BADORA3 | |
| SCHEMBL14635767 | 0.87 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL17302275 | 0.86 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL26382107 | 0.86 | AHCY (1.00) | AHCYADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| CN-113512587-B | Marker for cancer cell drug resistance, preparation combination for reversing cancer cell drug resistance and application thereof | 华中科技大学同济医学院附属同济医院 | 2022-03-18 | — | — | CN | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| CN-113512587-A | Marker for cancer cell drug resistance, preparation combination for reversing cancer cell drug resistance and application thereof | 华中科技大学同济医学院附属同济医院 | 2021-10-19 | — | — | CN | disclosed |
| WO-2013024048-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024049-A1 | PROTEIN CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| JP-2007099702-A | NF-kappaB INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | NAGOYA CITY UNIV | 2007-04-19 | — | — | JP | disclosed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | AHCY 412/4885ADORA2B 4314/4885ADORA3 3686/4885 |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | AHCY 4108/4885ADORA2B 1681/4885ADORA3 1608/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | AHCY 412/4885ADORA2B 4314/4885ADORA3 3686/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | AHCY 1436/4885ADORA2B 228/4885ADORA3 710/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | AHCY 412/4885ADORA2B 4314/4885ADORA3 3686/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | AHCY 1436/4885ADORA2B 228/4885ADORA3 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.